{"id":"W2149546612","doi":"10.3324/haematol.2014.111245","title":"A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E","year":2014,"lang":"en","type":"letter","venue":"Haematologica","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer; Jewish General Hospital","funders":"U.S. Public Health Service; National Institutes of Health; Université de Montréal; Jewish General Hospital; Centre National de la Recherche Scientifique; McGill University; Leukemia and Lymphoma Society","keywords":"Cytarabine; Medicine; Refractory (planetary science); Ribavirin; Myeloid leukemia; Internal medicine; Acute leukemia; Myeloid; Gastroenterology; Oncology; Pharmacology; Leukemia; Virology; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000958658,0.0004823325,0.0008899557,0.0002145076,0.0009017814,0.0008882632,0.0008437647,0.005786687,0.001655392],"category_scores_gemma":[0.002952483,0.000256812,0.0006390023,0.0002433185,0.0007424881,0.0007553681,0.0002535252,0.006371025,0.0006976693],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001713638,"about_ca_system_score_gemma":0.000904131,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008049376,"about_ca_topic_score_gemma":0.002394635,"domain_scores_codex":[0.999337,0.0003119366,0.00004919243,0.00008333686,0.0001101316,0.0001083585],"domain_scores_gemma":[0.9989531,0.0005668055,0.00007363211,0.00003054,0.0000753339,0.0003005963],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.05446179,0.005840249,0.02777112,0.0007627814,0.0007346336,0.1422912,0.0007205936,0.002481532,0.02377502,0.009961161,0.5126895,0.2185104],"study_design_scores_gemma":[0.1531774,0.05201942,0.0540724,0.0006659296,0.001045078,0.1668002,0.000913282,0.01914597,0.01671371,0.02814298,0.5070184,0.0002852583],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.321789,0.01206499,0.002240255,0.6162902,0.01705226,0.0008274075,0.000906411,0.0002325019,0.02859692],"genre_scores_gemma":[0.6657926,0.005303837,0.003039964,0.2918433,0.01689528,0.0003927743,0.0009877435,0.00006921298,0.01567525],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.005786687,"threshold_uncertainty_score":0.01243335,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.036414860354982,"score_gpt":0.3185717545133223,"score_spread":0.2821568941583403,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}